Companies › CERo Therapeutics Holdings
CERo Therapeutics Holdings: clinical trials, targets and expected readouts
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
Programs Drug Target Highest phase Conditions Next expected readout CER-1236 autologous chimeric engulfment receptor T-cell
– Phase 1 AML Dec 2026
Trials Registry id Drug Phase Conditions Area Expected readout NCT06834282 CER-1236 Phase 1 AML Oncology Dec 2026
From the company's SEC filings Cash of $1m on 2026-06-30; operating cash outflow about $10m a year; runway about 1 months at that burn, to Jul 2026
Press releases filed as 8-K in the last year:
Private offerings reported to the SEC (Form D) Agreements filed with the SEC (item 1.01), last two years 2026-08-31 · agreement with SRX Global Inc · On August 27, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), completed a secu 2026-07-17 · agreement with SRX Global Inc · On July 14, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) entered into a seco 2026-06-26 · agreement with SRX Health Solutions, Inc · On June 23, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) entered into an ame 2026-05-29 · agreement with SRX Health Solutions, Inc · On May 28, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a co 2026-05-01 · agreement with Keystone Capital Partners, LLC · On April 27, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a 2026-04-14 · agreement with Keystone Capital Partners, LLC · April 8, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a conv
Targets No annotated target.
Companies with the same targets –
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.
Built from ClinicalTrials.gov, CTIS, FDA, PubMed and OpenAlex, read every week; this page from the landscape of 2026-11-09. Phaseline reads registries; it is not investment or medical advice. Method and sources · Privacy · Contact